FDA Slots Plazomicin Test into Standard Safety Bucket for Labs
Published Date: 5/29/2025
Rule
Summary
The FDA is officially putting the plazomicin test system into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this cool new medical tool faster. If you make or use these tests, get ready for some updated guidelines that balance safety with easier approval.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Plazomicin Test Moves to Class II
The FDA is classifying the plazomicin test system as Class II (special controls). The special controls will be codified and apply to manufacturers and test developers, and the Agency says this classification provides reasonable assurance of safety and effectiveness while reducing regulatory burdens.
Faster Patient Access to Test
The FDA says classifying the plazomicin test system into Class II will enhance patients' access to this diagnostic test by reducing regulatory burdens while providing reasonable assurance of safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-09617, Removal of Obsolete Regulations
FSA is cleaning house by removing old, unnecessary rules to make things simpler and clearer for everyone. This update won’t affect current or past customers, and it won’t cost anyone extra. It’s all about cutting clutter and making the rules easier to follow!
Next: 2025-09639, Medical Devices; Immunology and Microbiology Devices; Classification of the Zika Virus Serological Reagents
The FDA is officially putting Zika virus blood test tools into a special safety group called Class II. This means these tests will have clear rules to keep them safe and working well, helping patients get better access to these important tools faster. This change affects companies making these tests and aims to cut down on red tape without costing extra time or money.